Heart Problem Pauses Hepatitis C Drug Study
August 8, 2012
Bristol-Myers suspends hepatitis C treatment study, cites possible cardiac concern
Article by: TOM MURPHY , Associated Press
Updated: August 2, 2012 – 11:34 AM
Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment after at least one patient suffered heart failure.
The New York company hasn’t determined the cause or whether it is tied to the potential treatment, so it is examining all patients who took the drug.
Continue reading this entire article:
Can GKT137831 - a NOX Inhibitor - Stop Liver Fibrosis?
Hep C Trial with Sovaprevir Has 85% Success Rate